To enlighten investors on the impact of these breakthroughs and the opportunities they should create, we began publishing Big Ideas in 2017. This annual research report seeks to highlight

Multi-Cancer Screening
•
As population-scale clinical utility 
data proliferates, ARK believes a 
$1,500 price tag will unlock the 
multi-cancer screening market for 
those aged 65 to 80—the age range in 
which the incidence of cancer peaks.
•
As prices drop below $1,000, nearly 
all age groups above 40 years could 
be screened for cancer cost-
effectively, potentially saving up to 
1.4 million human life years in the US 
alone.
Thanks To Rapidly Declining 
Costs, Multi-Cancer Screening 
Is Approaching A 
Reimbursable Price Point
$0
$50
$100
$150
$200
$250
$300
$350
20
30
40
50
60
70
Incremental Cost / Life
-Year Gained* 
(Thousands, USD)
Patient Age
$2,000 Test
$1,500 Test
$1,200 Test
$1,000 Test
Willingness-to-Pay
The Multi-Cancer Screening Market: 
Costs and Reimbursement
Eligible for Reimbursement ($100,000/Life-Year (LY) Threshold) 

---

•
Note: Narrow panels seek to detect a limited number of cancers, typically about a dozen (12). Broad panels, or pan-cancer panels, aim to find as many as fifty different cancers. 
Forecasts are inherently limited and cannot be relied upon. | Source: ARK Investment Management LLC., 2020
103
Multi-Cancer Screening
•
Routine blood-based, multi-
cancer screening combined with 
improvements in single-cancer 
screening could prevent 40% of 
metastatic diagnoses and 
increase loco-regional 
diagnoses by 10%.
•
Even without improvements in 
cancer therapy, ARK estimates 
that earlier intervention could 
prevent 66,000 cancer deaths 
per year in the US alone.